Biotechnology valuations are getting cheaper: What are the emerging opportunities?
About this episode
The Beyond Markets podcast channel is wrapping up on a high note at the end of 2025. But do not worry! The conversation continues on our podcast Moving Markets by Julius Baer, where we'll be sharing fresh insights and analysis on current market developments.
Subscribe to Moving Markets on Spotify
Subscribe to Moving Markets on Apple Podcasts
In this episode, we take a closer look at the biotechnology sector which has seen share prices come under pressure this year. Valuations have become cheaper even as clinical trial developments continue. We explore emerging new therapies in the sector as well as the potential for M&A. Learn more in this discussion with Julius Baer experts Yaw Shin Wong, Equity Specialist Asia and Fabian Wenner, Healthcare analyst for Julius Baer Research.
Chapters
- (01:01) - Review of recent performance of sector
- (02:30) - Fabian’s current take on biotech
- (03:02) - Are fundamentals for biotech intact?
- (05:30) - Clinical trials that could yield interesting results
- (07:08) - Opinions on the mRNA-based therapies
- (08:42) - M&A in the biotech sector
Get every episode summarized
Each time Beyond Markets publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Beyond Markets
Moving Markets – the new home for Beyond Markets content
Beyond Markets
Secular Outlook 2026: A CIO Perspective on the Forces Shaping the Decade Ahead
Beyond Markets
The Week in Markets: Economically-sensitive stock market indices break to new hi...
Beyond Markets
China Conversations: AI momentum and policy tailwinds into 2026
Beyond Markets